What technical signals does Kala Pharmaceuticals (KALA) have?

Kala Pharmaceuticals current technical signals: no active technical signal.

Is Kala Pharmaceuticals a cup-and-handle pattern?

No. Kala Pharmaceuticals has no valid cup-and-handle signal right now.

What are Kala Pharmaceuticals's financials and valuation?

Kala Pharmaceuticals's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Kala Pharmaceuticals

KALA · Nasdaq

$0.5073-9.57%

2026-09-04 close

Kala Pharmaceuticals last closed at $0.5073 (-9.57%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…

No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions

277 picks

Next-day win rate

44.2%

Avg next-day

-0.28%

vs market

-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

EntryAccount sizeStopTarget (optional)Risk per trade (%)

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

Overall: 건강관리 639/745 · top 86%

Factor composite · relative position in sector

PER — · PBR 0.01 — own-history percentile 0/100 · 100/100

Open self-history band

PER0/100

PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024

Distress zoneFinancial-metric reference signal

Altman Z'' zoneZ'' -39.67

Distress

Grey

Safe

The marker shows the current Z'' value within the displayed zones.

Altman Z'': -39.67
Beneish M-Score: —
Sloan accrual: -16.45%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

4/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score4/9

Profitability

Positive ROANot passed
Positive OCFNot passed
Improving ΔROAPass
Accruals (OCF > net income)Pass

Leverage & liquidity

Lower debtPass
Higher current ratioNot passed
No new sharesPass

Efficiency

Higher gross marginNot passed
Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Connections

AI-extracted related companies · for reference

Competitors

EyePoint PharmaceuticalsPrice comovement r=0.11 (1 year)SandozBausch + Lomb Alcon Johnson & JohnsonPrice comovement r=0.02 (1 year)NovartisRegeneron PharmaceuticalsPrice comovement r=0.04 (1 year)Apellis PharmaceuticalsAstellas Pharma

Same theme

KOL

🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About Kala Pharmaceuticals

What technical signals does Kala Pharmaceuticals (KALA) have?: Kala Pharmaceuticals current technical signals: no active technical signal.
Is Kala Pharmaceuticals a cup-and-handle pattern?: No. Kala Pharmaceuticals has no valid cup-and-handle signal right now.
What are Kala Pharmaceuticals's financials and valuation?: Kala Pharmaceuticals's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy